

L10 ANSWER 3 OF 22 USPATFULL

ACCESSION NUMBER: 94:11246 USPATFULL
TITLE: Powdered dairy creamer
INVENTOR(S): Fazio, Susan C., P.O. Box 302, Oldwick, NJ, United States 08858

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5284674		19940208
APPLICATION INFO.:	US 1992-881485		19920511 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pratt, Helen F.		
LEGAL REPRESENTATIVE:	Butch, III, Peter		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	661		

SUMM Examples of vitamins and minerals that can be added as nutritional supplements to the powdered dairy creamer **compositions** of the present invention include the vitamin E-based antioxidants disclosed above, vitamins A and D, which are typically added in corn oil, cyanocobalamine, calcium gluconate, potassium citrate, magnesium aspartate, selenium chelate, zinc succinate, calcium pantothenate, niacinamide ascorbate, pyridoxine hydrochloride, **coenzyme Q 10**, beta carotene and the like.

CLM What is claimed is:

13. The powdered dairy creamer **composition** of claim 1, further comprising one or more nutritional supplements selected from the group consisting of vitamin E dl alpha. . . vitamin A, vitamin D, calcium gluconate, potassium citrate, magnesium aspartate, selenium chelate, zinc succinate, calcium pantothenate, niacinamide ascorbate, pyridoxine hydrochloride, **coenzyme Q 10**, beta carotene and cyanocobalamine.

16. The powdered dairy creamer **composition** of claim 14 further comprising one or more nutritional supplements selected from the group consisting of vitamin E dl alpha. . . vitamin A, vitamin D, calcium gluconate, potassium citrate, magnesium aspartate, selenium chelate, zinc succinate, calcium pantothenate, niacinamide ascorbate, pyridoxine hydrochloride, **coenzyme Q 10**, beta carotene and cyanocobalamine.

L12 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER: 87:22588 USPATFULL
TITLE: Pharmaceutical formulations containing coenzyme
Q.sub.10 suitable for topic administration
INVENTOR(S): Bertelli, Alberto, Milan, Italy
PATENT ASSIGNEE(S): Italfarmaco S.A., Lugano, Switzerland (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4654373		19870331
APPLICATION INFO.:	US 1985-711034		19850312 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1983-476556, filed on 18 Mar 1983, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1982-20274	19820319
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schenkman, Leonard	
ASSISTANT EXAMINER:	Lipovsky, Joseph A.	
LEGAL REPRESENTATIVE:	Schneider, Walter H.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	394	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM In spite of the fact that the therapeutic action of **Coenzyme Q.sub.10** is clearly evident in inflamed and impaired tissues such as gingival mucous membranes, in the periodontopathies, or in the penfigus or lichen planus, its therapeutic use has been carried out up to now only by the oral or **parenteral** administration route.

SUMM Although the effective concentrations displaying an effective action at cellular and tissutal levels are very low, the oral and **parenteral** administration of **Coenzyme Q.sub.10** makes it possible to remedy to the enzymatic system deficiencies which are responsible for a variety of diseases.

SUMM Recently, the **parenteral** route has been used to obtain higher tissutal concentrations of **Coenzyme Q.sub.10**. However, this technique is scarcely advantageous, due to the very low solubility of **Coenzyme Q.sub.10** in excipients compatible with its **parenteral** administration.

SUMM . . . is localized to the ill region, thereby reducing the side effects which could be produced by the unnecessary oral or **parenteral** administration of **Coenzyme Q.sub.10**.

L10 ANSWER 10 OF 22 USPATFULL

ACCESSION NUMBER: 88:67394 USPATFULL

TITLE: Pharmaceutical compositions having vasodilating and antianoxic activities

INVENTOR(S): Brasey, Pierre-Noel, Communy, Switzerland

PATENT ASSIGNEE(S): Seuref A.G., Vaduz, Liechtenstein (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4778798		19881018
APPLICATION INFO.:	US 1986-892247		19860731 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1985-3344	19850802
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Friedman, Stanley J.	
LEGAL REPRESENTATIVE:	Bucknam and Archer	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	154	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical **compositions** having vasodilating and antianoxic activities containing an **ubiquinone** or **Coenzyme Q.sub.10** and a vasodilating compound selected from the groups of ergotamine, Rauwolfia, vincamine alkaloids, calcium antagonists, .beta.-blockers, papaverine, Ginkgo biloba, xanthine. . .

SUMM The present invention relates to pharmaceutical **compositions** containing a combination of a **ubiquinone** coenzyme and one or more compounds having vasodilating activity.

SUMM The pharmaceutical **compositions** according to the invention besides comprising **Coenzyme Q.sub.10**, which exerts a metabolically healing action, correcting disorders due to tissular hypoxia related to a poor vascularization, also contain one. . .

DETD The **compositions** of the invention will be formulated according to conventional techniques, with the usual excipients. For oral administration, **Coenzyme Q.sub.10** and the vasodilating compound(s) may be formulated in form of tablets, capsules, dragees, sugar-coated pills, granulates, syrups, ampoules, containing pharmaceutically. . .

CLM What is claimed is:
. . . to atherosclerosis, hypertension, senescence or vasal spasms, which consists of administering to a living subject in need of treatment a **composition** containing an effective amount of **Coenzyme Q.sub.10** and nifedipine, said **Coenzyme Q.sub.10** and said nifedipine being in the ratio of ranging from 1:100 to 100:1.

L10 ANSWER 4 OF 22 USPATFULL

ACCESSION NUMBER: 91:34378 USPATFULL

TITLE: Therapy with coenzyme Q.sub.10 of patients having AIDS or other retroviral diseases

INVENTOR(S)': Langsjoen, Per H., Temple, TX, United States
Folkers, Karl A., Austin, TX, United States
Langsjoen, Peter H., Bullard, TX, United States

PATENT ASSIGNEE(S): The Board of Regents, The University of Texas System,
Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5011858		19910430
APPLICATION INFO.:	US 1987-99363		19870921 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-33301, filed on 30 Mar 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Morris, Theodore		
ASSISTANT EXAMINER:	Brunsman, David M.		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	423		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CLM What is claimed is:

. . . the treatment of an individual having a retrovirus infection, the method comprising administering to the individual an amount of a **composition** consisting essentially of **coenzyme Q.sub.10** in an amount effective to alleviate symptoms of the retrovirus infection.

10. The method of claim 8 wherein the effective amount of the **composition** contains between about 25 mg and about 400 mg **coenzyme Q.sub.10**.

11. The method of claim 8 wherein the effective amount of the **composition** contains about 200 mg **coenzyme Q.sub.10**.